| [1] |
Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care[J]. Postgrad Med J, 2007, 83(975): 66-68.
|
| [2] |
Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital[J]. Curr Clin Pharmacol, 2010, 5(4): 288-297.
|
| [3] |
Masclee GM, Sturkenboom MC, Kuipers EJ, et al. A benefit-risk assessment of the use of proton pump inhibitors in the elderly[J]. Drugs Aging, 2014, 31(4): 263-282.
|
| [4] |
Cerreta F, Eichler HG, Rasi G, et al. Drug policy for an aging population——the European Medicines Agency’s geriatric medicines strategy[J].N Engl J Med, 2012, 367(21): 1972-1974.
|
| [5] |
陈敏敏，郑松柏．老年人药代动力学的特点[J]．老年医学与保健，2011，17(3): 189-191.
|
| [6] |
刘菲，郑松柏．重视质子泵抑制剂的安全性[J]．中国新药与临床杂志，2012，31(9): 493-498.
|
| [7] |
李小雯，郑松柏．CYP2C19基因多态性及其与PPI疗效影响研究进展[J]．中国新药与临床杂志，2013，32(10): 775-779.
|
| [8] |
Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetic study of esomeprazole in the elderly[J]. Clin Pharmacokinet, 2001, 40(2): 145-150.
|
| [9] |
姚光弼．质子泵抑制剂的新成员——埃索美拉唑[J]．中华消化杂志，2002，22(4): 233-235.
|
| [10] |
Desilets AR, Asal NJ, Dunican KC, et al. Considerations for the use of proton-pump inhibitors in older adults[J]. Consult Pharm, 2012, 27(2): 114-120.
|
| [11] |
Ferron GM, Preston RA, Noveck RJ, et al. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction[J]. Clin Ther, 2001, 23(8): 1180-1192.
|
| [12] |
Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors[J]. Aliment Pharmacol Ther, 2000, 14(8): 963-978.
|
| [13] |
Ray S, Delaney M, Muller AF, et al. Proton pump inhibitors and acute interstitial nephritis[J]. BMJ, 2010, 341: c4412.
|
| [14] |
Toms-Whittle LM, John LH, Buckley DA, et al. Drug-induced subacute cutaneous lupus erythematosus associated with omeprazole[J]. Clin Exp Dermatol, 2011, 36(3): 281-283.
|
| [15] |
Tröger U, Reiche I, Jepsen MS, et al. Esomeprazole-induced rhabdomyolysis in a patient with heart failure[J]. Intensive Care Med, 2010, 36(7): 1278-1279.
|
| [16] |
Targownik LE, IAx LM, Leung S, et a1. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss[J]. Gastroenterology, 2010, 138(3): 896-904.
|
| [17] |
Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors[J]. Pharmacotherapy, 2008, 28(8): 951-959.
|
| [18] |
Philip O, Katz MD, Lauren B, et al. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease[J]. Am J Gastroenterol, 2013, 108(3): 308-328.
|
| [19] |
Leontiadis GI, Moayyedi P. Proton pump inhibitors and risk of bone fractures[J]. Current Treatment Options in Gastroenterology, 2014, 12: 414-423.
|
| [20] |
Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture[J]. JAMA, 2006, 296(24):2947-2953.
|
| [21] |
Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures[J]. CMAJ, 2008, 179(4): 319-326.
|
| [22] |
Vestergaard P, Rejnmark L, Mosekilde L, et al. Has mortality after a hip fracture increased[J]?J Am Geriatr Soc, 2007, 55(11): 1720-1726.
|
| [23] |
李慧博，赵荣生．质子泵抑制剂临床治疗与骨折风险的循证评价[J]．临床药物治疗杂志，2014，12(3): 1-8.
|
| [24] |
国家食品药品监督管理总局．警惕质子泵抑制剂的骨折、低镁血症风险以及与氯吡格雷的相互作用[J]．中国药房，2013，24(5): 427.
|
| [25] |
Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing[J]? Cleve Clin J Med, 2011, 78(1): 39-49.
|
| [26] |
Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs[J]. JAMA, 2004, 292(16): 1955-1960.
|
| [27] |
Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study[J]. Arch Intern Med, 2007, 167(9): 950-955.
|
| [28] |
Hermos JA, Young MM, Fonda JR, et al. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed[J]. Clin Infect Di, 2012, 54(1): 33-42.
|
| [29] |
Roughead EE, Ramsay EN, Pratt NL, et al. Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia[J]. Med J Aust, 2009, 190(3): 114-116.
|
| [30] |
Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis[J]. CMAJ, 2011, 183: 310-319.
|
| [31] |
Johnstone J, Nerenberg K, Loeb M, et al. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia[J]. Aliment Pharmacol Ther, 2010, 31(11): 1165-1177.
|
| [32] |
Giuliano C, Wilhelm SM, Kale-Pradhan PB, et al. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis[J]. Xpert Rev Clin Pharmacol, 2012, 5(3): 337-344.
|
| [33] |
Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis[J]. Gut, 2014, 63(4): 552-558.
|
| [34] |
Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth[J]. Aliment Pharmacol Ther, 2006, 23(1): 3-10.
|
| [35] |
Leonard J, Marshall JK, Moayyedi P, et al. Systematic review of the risk of enteric infection in patients taking acid suppression[J]. Am J Gastroenterol, 2007, 102(9): 2047-56.
|
| [36] |
McDonald EG, Milligan J, Frenette C, et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile infection[J]. JAMA, 2015, 175(5): 784-91.
|
| [37] |
Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent clostridium difficile infection[J]. Arch Intern Med, 2010, 170(9): 772-778.
|
| [38] |
Kim JW, Lee KL, Jeong JB, et al. Proton pump inhibitors as a risk factor for recurrence ofClostridium-difficile–associated diarrhea[J]. World J Gastroenterol, 2010, 16(28): 3573-3577.
|
| [39] |
Cadle RM, MansouriMD, Logan N, et al. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis[J]. Am J Health Syst Pharm, 2007, 64(22): 2359-2363.
|
| [40] |
Dial S, Alrasadi K, Manoukian C, et al. Risk of clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies[J]. CMAJ, 2004, 171(1): 33-38.
|
| [41] |
Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis[J]. PLoS One, 2012, 7(12): e50836.
|
| [42] |
Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy[J]. Dig Dis Sci, 2011, 56(4): 931-950.
|
| [43] |
Sarzynski E, Puttarajappa C, Xie Y, et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study[J]. Dig Dis Sci, 2011, 56(8): 2349-53.
|
| [44] |
McColl KE. Effect of proton pump inhibitors on vitamins and iron[J]. Am J Gastroenterol, 2009, 104(Suppl 2): S5-9.
|
| [45] |
Allen RH, Seetharam B, Podell E, et al. Effect of proteolytic enzymes on the binding of cobalamin to R protein and intrinsic factor. In vitro evidence that a failure to partially degrade R protein is responsible for cobalamin malabsorption in pancreatic insufficiency[J]. J Clin Invest, 1978, 61(1): 47-54.
|
| [46] |
Hirschowitz BI, Worthington J, Mohnen J, et al. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors[J]. Aliment Pharmacol Ther, 2008, 27(11): 1110-1121.
|
| [47] |
Den Elzen WP, Groeneveld Y, De Rujiter W, et al. Long-term use of proton pumpinhibitors and vitamin B12 status in elderly individuals[J]. Aliment Pharmacol Ther, 2008, 27(6): 491-497.
|
| [48] |
FDA. FDA Drug Safety Podcast for Healthcare Professionals: clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs).[2012-09-02]
URL
|
| [49] |
Toh JW, Ong E, Wilson R, et al. Hypomagnesaemia associated with long-term use of proton pump inhibitors[J]. Gastroenterology Report(Oxf), 2015, 3(3): 245-253.
|
| [50] |
刘改芳．长期应用质子泵抑制剂与低镁血症[J]．中华消化杂志，2013，33(7): 497-499.
|
| [51] |
Lemon TI. Proton pump inhibitors and hypomagnesemia monitoring[J]. Int J Gen Med, 2013, 6(8): 675.
|
| [52] |
Stolte M. Fundic gland polyps: a rare, innocuous, and reversible disturbance[J]. Gastroenterology, 1993, 105(5): 1590-1591.
|
| [53] |
Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update[J]. Drug Saf, 2014, 37(4): 201-211.
|
| [54] |
Labenz J, Petersen KU, RöschW, et al. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole[J]. Aliment Pharmacol Ther, 2003, 17(8): 1015-1019.
|
| [55] |
Moreira Dias L.Pantoprazole a proton pump inhibitor[J]. Clin Drug Investig, 2009, 29(Suppl 2): 3-12.
|
| [56] |
Goirand F, Le Ray I, Bardou M, et al. Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease[J]. Drug MetabToxicol, 2014, 10(9): 1301-1311.
|
| [57] |
Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J]. JAMA, 2009, 301(9): 937-944.
|
| [58] |
Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention[J]. Am J Cardiol, 2011, 107(6): 871-878.
|
| [59] |
Alkhatib AA, Elkhatib FA, Khatib OF, et al. Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations[J]? Am J Gastroenterol, 2010, 105(5): 1211.
|
| [60] |
Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or witout omeprazole in coronary artery disease[J]. N Engl J Med, 2010, 363(20): 1909-1917.
|
| [61] |
O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor:an analysis of two randomised trials[J].Lancet, 2009, 374(9694): 989-997.
|
| [62] |
王悦，李雅君．质子泵抑制剂对冠心病患者经皮冠状动脉介入术后双重抗血小板治疗的影响[J]．中国医药，2013，8(1): 10-11.
|
| [63] |
Gerson LB, McMahon D, Olkin I, et al. Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature[J]. Dig Dis Sci, 2012, 57: 1304-1313.
|
| [64] |
Sharvari M, Bhurke B, Pharm MS, et al. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome[J].Pharmacotherapy, 2012, 32(9): 809-818.
|
| [65] |
中华医学会消化病学分会．2014年中国胃食管反流病专家共识意见[J]．中华消化杂志，2014，34(10): 649-661.
|
| [66] |
Katelaris PH, Seow F, Lin BP, et al. Effect of age, helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men[J]. Gut, 1993, 34(8): 1032-1037.
|
| [67] |
Goldschmiedt M, Barnett CC, Schwarz BE, et al. Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women[J].Gastroenterology, 1991, 101(4): 977-90.
|
| [68] |
吴本俨，王孟薇，李园．老年人24小时胃内pH节律变化特点[J]．中华老年医学杂志，1999，18(3): 147.
|
| [69] |
郑松柏，项平，徐富星，等．空腹胃液量及胃内酸度的增龄变化[J]．中华老年医学杂志，2008，27(4): 283.
|
| [70] |
Zhang W, Zheng SB, Zhuang Y, et al. H+/K+ATPase expression in human parietal cells and gastric acid secretion in elderly individuals[J]. J Dig Dis, 2013, 14(7): 366-372.
|
| [71] |
Hurwitz A, Brady DA, Schaal SE, et al. Gastric acidity in older adults[J].JAMA, 1997, 278(8): 659-662.
|
| [72] |
庄艳，郑松柏．老年人胃酸的现代认识[J]．老年医学与保健, 2012，18(3): 186-189.
|
| [73] |
Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors[J]. Drugs Aging, 2002, 19(12): 911-927.
|
| [74] |
Baldi F. Lansoprazole Oro-Dispersible tablet pharmacokinetics and therapeutic use in acid-related disorders[J].Drugs, 2005, 65(10): 1419-1426.
|
| [75] |
郑松柏．老年人胃食管反流病的特点[J]．中华老年医学杂志，2009，28(4): 265-266.
|
| [76] |
中华消化杂志编委会．消化性溃疡病诊断与治疗规范建议(2013年，深圳) [J]．中华消化杂志，2014，34(2): 73-76.
|
| [77] |
中华医学杂志编辑委员会．应激性溃疡防治建议[J]．中华医学杂志，2002，82(14): 1000-1001.
|
| [78] |
急性非静脉曲张性上消化道出血诊治指南(2009，杭州)[J]．中华内科杂志，2009，48(10): 891-894.
|
| [79] |
袁耀宗，杨云生，吴开春．2012年《溃疡出血患者处理指南》的解读与质子泵抑制剂的临床应用[J]．中华消化杂志，2012，2(7): 487-489.
|
| [80] |
中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌协作组，刘文忠，谢勇，等．第四次全国幽门螺杆菌感染处理共识报告[J]．中华内科杂志，2012，51(10): 832-837.
|
| [81] |
吴开春，刘震雄．非甾体类抗炎药与消化性溃疡[J]．中华消化杂志，2008，28(7): 439-441.
|
| [82] |
诸琦，熊慧芳，吴巍．非甾体类抗炎药临床应用调查[J]．中华消化杂志，2008，28(12): 842-846.
|
| [83] |
Iwamoto J, Saito Y, Honda A, et al. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy[J].World J Gastroenterol, 2013, 19(11): 1673-82.
|
| [84] |
抗血小板药物消化道损伤的预防和治疗中国专家共识组．抗血小板药物消化道损伤的预防和治疗中国专家共识(2012更新版) [J]．中华内科杂志，2013，52(3): 264-270.
|
| [85] |
Cryer B, Bhatt DL, Lanza FL, et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial[J]. Am J Gastroenterol, 2011, 106(2): 272-277.
|
| [86] |
Lanza FL, Chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications[J]. Am J Gastroenterol, 2009, 104(3): 728-738.
|
| [87] |
Rostom A, Moayyedi P, Hunt R, et al. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks[J]. Aliment Pharmacol Ther, 2009, 29(5): p81-96.
|
| [88] |
Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers[J]. Cochrane Database Syst Rev, 2002, 4: CD002296.
|
| [89] |
Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease[J]. N Engl J Med, 2010, 363(20): 1909-1917.
|
| [90] |
Christensen S, Riis A, Nørgaard M, et al. Perforated peptic ulcer: use of pre-admission oral glucocorticoids and 30-day mortality[J]. Aliment Pharmacol Ther, 2006, 23(1): 45-52.
|
| [91] |
Lee HC, Cho DY, Lee WY, et al. Pitfalls in treatment of acute cervical spinal cord injury using high-dose methylprednisolone: a retrospect audit of 111 patients[J]. Surg Neurol, 2007, 68(Suppl 1): S37-41.
|
| [92] |
Park CH, Lee SK. Preventing and controlling bleeding in gastric endoscopic submucosal dissection[J].Clin Endosc, 2013, 46(5): 456-462.
|
| [93] |
赵飞，杨建民．内镜黏膜下剥离术后溃疡的治疗[J]．中华临床医师杂志(电子版)，2013，7(20): 9014-9016.
|
| [94] |
中华医学会消化病学分会，中国慢性胃炎共识意见(2012年，上海)[J]．中华消化杂志，2013，33(1): 5-16.
|
| [95] |
Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia[J]. J Gastroenterol Hepatol, 2012, 27(4): 626-641.
|
| [96] |
Miwa H, Kusano M, Arisawa T, et al. Evidence-based clinical practice guidelines for functional dyspepsia[J].J Gastroenterol, 2015, 50(2): 125-139.
|
| [97] |
中华医学会老年医学分会，中华老年医学杂志编委会．老年人功能性消化不良诊治专家共识[J]．中华老年医学杂志，2015，34(7): 698-705.
|